Core Viewpoint - The company has successfully developed a new veterinary drug, Mirtazapine Ointment, which has been approved as a Class V new veterinary drug by the Ministry of Agriculture and Rural Affairs, indicating a significant advancement in the company's product offerings and innovation capabilities [1][9]. Group 1: New Veterinary Drug Information - New veterinary drug name: Mirtazapine Ointment [2] - Developed by: A collaboration of multiple companies including Qingdao Weilan Pet Biotechnology Co., Ltd., Qingdao Kangdian Animal Pharmaceutical Co., Ltd., and others [2]. - Registration certificate number: (2025) New Veterinary Drug Certificate No. 82 [3]. - Monitoring period: 3 years [3]. - Main ingredient: Mirtazapine [3]. - Indication: Used to control weight loss in cats [3]. - Dosage: Apply a 3.8 cm strip of ointment (equivalent to 2 mg of Mirtazapine) to the inner side of the cat's ear once daily for 14 days, alternating between ears [3]. Group 2: Research and Development - The development of Mirtazapine Ointment involved significant investment, totaling 1.8622 million yuan in research and development costs [4]. - The product has undergone laboratory research, clinical trials, and new veterinary drug registration processes, culminating in the recent issuance of the registration certificate [4]. Group 3: Market Background - Weight loss and decreased appetite in cats are significant clinical signs of potential diseases, which can lead to malnutrition, organ dysfunction, and weakened immunity if not addressed [5]. - The new veterinary drug aims to meet the clinical needs of the pet market, characterized by controllable quality, safety, efficacy, ease of administration, and high compliance [5]. Group 4: Future Procedures - Before the product can be marketed, it must obtain the veterinary product approval number from the Ministry of Agriculture and Rural Affairs, as per relevant regulations [7]. Group 5: Impact on the Company - The acquisition of the new veterinary drug certificate reflects the company's commitment to technological innovation and increased R&D investment, enhancing its product portfolio and potentially providing new growth opportunities for the business [9].

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-034 青岛蔚蓝生物股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》等的相关规定，经农业农村部审 查，批准青岛蔚蓝生物股份有限公司（以下简称"公司"）及全资子公司青岛蔚 蓝至宠生物科技有限公司、青岛康地恩动物药业有限公司与其他单位联合申报的 "米氮平软膏"为五类新兽药，并于近日核发了《新兽药注册证书》（农业农村 部公告第 935 号）。 一、新兽药的基本信息 新兽药名称：米氮平软膏 研制单位：青岛蔚蓝至宠生物科技有限公司、青岛康地恩动物药业有限公司、 上海汉维生物医药科技有限公司、广东润华药业有限公司、青岛蔚蓝生物股份有 限公司、南京威特动物药品有限公司、江西瑞德制药有限公司、天津市中升挑战 生物科技有限公司。 新兽药注册证书号：（2025）新兽药证字 82 号 监测期：3 年 注册分类：五类 主要成分：米氮平 作用与用途：用于控制猫体重减轻。 米氮平软膏是由公司及全资子公司青岛蔚蓝至宠 ...

Core Viewpoint - Company Blue Biological (603739.SH) has received approval from the Ministry of Agriculture and Rural Affairs for its new veterinary drug "Mirtazapine Ointment," classified as a Category V new veterinary drug, addressing significant clinical signs in cats such as decreased appetite and weight loss [1] Group 1 - The Ministry of Agriculture and Rural Affairs has issued a new veterinary drug registration certificate for "Mirtazapine Ointment," developed by the company and its subsidiaries [1] - The product aims to meet clinical needs in the pet market, particularly for cats, by addressing potential health issues like malnutrition and organ dysfunction due to decreased appetite [1] - The ointment is characterized by controllable quality, safety, effectiveness, ease of administration, and high compliance [1] Group 2 - Currently, the company has not been able to find any similar products in circulation or their market share through public channels [1]

Core Viewpoint - The company has received approval from the Ministry of Agriculture and Rural Affairs for its new veterinary drug, "Mirtazapine Ointment," which addresses significant clinical signs in cats such as decreased appetite and weight loss, potentially leading to severe health issues if untreated [1] Group 1: Product Development - The company, along with its subsidiaries, has successfully developed a new veterinary drug classified as a Category V new veterinary drug, which has been officially registered [1] - The new product, Mirtazapine Ointment, is designed to meet clinical needs in the pet market, particularly for cats experiencing appetite loss [1] Group 2: Product Characteristics - The Mirtazapine Ointment is characterized by controllable quality, safety and effectiveness, ease of administration, and high compliance [1] Group 3: Market Context - Currently, the company has not been able to find any information regarding the sales status and market share of similar products in circulation through public channels [1]

Core Viewpoint - Qingdao Weilan Biological Co., Ltd. and its subsidiaries have received approval for the new veterinary drug "Mirtazapine Ointment" as a Class V new veterinary drug from the Ministry of Agriculture and Rural Affairs of China [1] Group 1 - The approval was granted based on the relevant regulations including the "Veterinary Drug Management Regulations" and the "Veterinary Drug Registration Measures" [1] - The new veterinary drug registration certificate has been issued recently [1]

Core Viewpoint - The company announced the approval of "Mirtazapine Ointment" as a new veterinary drug, which is expected to create a new growth point for its business [1] Group 1: Product Development - The product "Mirtazapine Ointment" is classified as a Category V new veterinary drug [1] - The ointment is primarily used for controlling weight loss in cats [1] - The research and development of this product involved collaboration with multiple units and a total investment of 1.8622 million yuan [1] Group 2: Business Impact - The acquisition of the new veterinary drug registration certificate is anticipated to contribute positively to the company's performance [1]

Core Insights - The animal vaccine sector saw a rise of 1.41%, ranking 8th among concept sectors, with 15 stocks increasing in value, led by Shenlian Bio, Kanghua Bio, and Tiankang Bio, which rose by 9.71%, 8.60%, and 2.02% respectively [1][2] - The sector experienced a net outflow of 6.53 million yuan in capital, with seven stocks receiving net inflows, primarily led by Guoyao Modern, which saw a net inflow of 29.79 million yuan [2][3] - The top three stocks by net inflow ratio were Guoyao Modern at 17.35%, Kexing Pharmaceutical at 9.18%, and Luoniushan at 9.02% [3] Stock Performance - Guoyao Modern had a daily increase of 1.35% with a turnover rate of 1.14% and a net capital flow of 29.79 million yuan [3] - Kexing Pharmaceutical increased by 0.54% with a turnover rate of 2.79% and a net capital flow of 24.08 million yuan [3] - Luoniushan rose by 1.11% with a turnover rate of 2.44% and a net capital flow of 16.07 million yuan [3] Declining Stocks - Xianfeng Holdings, Biotech Shares, and Yongshun Bio were among the stocks with the largest declines, falling by 3.05%, 1.04%, and 0.60% respectively [1][4] - Other notable declines included Tian Kang Bio at 2.02% and Ruipu Bio at 0.56% [4]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-033 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 单位：万元 | 担保人 | 被担保人 | 本次担保 | 担保余额 | 担保余额占公司 2024 年 | | --- | --- | --- | --- | --- | | | | 金额 | （含本次） | 经审计净资产的比例 | | 青岛蔚蓝生物股份有限 | 青岛蔚蓝生物集团有限 | 10,000.00 | 24,597.15 | 14.15% | | 公司 | 公司 | | | | 一、 担保情况概述 （一）担保基本情况 2025 年 8 月 5 日，青岛蔚蓝生物股份有限公司（以下简称"公司"）与北京 银行股份有限公司青岛分行签署了《最高额保证合同》，为公司全资子公司蔚蓝 生物集团在该行开展的授信业务提供连带责任保证担保，担保总额为人民币 10,000.00 万元。 截至本公告日，公司对资产负债率为 70%以下的控股子公司的可用担 ...

Core Viewpoint - The A-share market has seen a strong performance in the biopharmaceutical sector, particularly in vaccine stocks, driven by the release of the 2025 treatment plan for Chikungunya virus, highlighting the lack of available vaccines in China [1][2] Group 1: Market Performance - Shenyuan Biological (申联生物) rose by over 10%, with a year-to-date increase of 42.60% and a market capitalization of 3.203 billion [2] - Global Printing (环球印务) increased by 9.96%, with a market cap of 3.252 billion and a year-to-date rise of 34.04% [2] - Guanhao Biological (冠昊生物) saw a 7.70% increase, with a market cap of 4.969 billion and a year-to-date increase of 55.65% [2] - Sealy Medical (塞力医疗) rose by 5.60%, with a market cap of 6.055 billion and an impressive year-to-date increase of 339.06% [2] - Other notable performers include Kanglao Weishi (康乐卫士) up 4.98%, Jinhai Biological (金河生物) up 4.62%, and Weilan Biological (蔚蓝生物) up 4.41% [1][2] Group 2: Regulatory and Health Measures - The 2025 Chikungunya virus treatment plan emphasizes preventive measures such as eliminating mosquito breeding sites and using repellents [1] - Travelers to Chikungunya endemic areas are advised to enhance their preventive awareness to avoid infection [1] - Currently, there is no available vaccine for the Chikungunya virus in China, indicating a potential market opportunity for vaccine development [1]

Core Viewpoint - The A-share market has seen a strong performance in the biopharmaceutical sector, particularly in vaccine stocks, driven by the release of the 2025 treatment plan for Chikungunya virus, which has heightened awareness and demand for related medical solutions [1][2]. Group 1: Stock Performance - Shenyuan Biological (申联生物) rose by 10.33%, with a market capitalization of 3.203 billion [2] - Global Printing (环球印务) increased by 9.96%, with a market capitalization of 3.252 billion [2] - Guanhao Biological (冠昊生物) saw a rise of 7.70%, with a market capitalization of 4.969 billion [2] - Seer Medical (塞力医疗) grew by 5.60%, with a market capitalization of 6.055 billion [2] - Kanglao Guardian (康乐卫士) increased by 4.98%, with a market capitalization of 4.793 billion [2] - Jinhai Biological (金河生物) rose by 4.62%, with a market capitalization of 5.594 billion [2] - Weilan Biological (蔚蓝生物) increased by 4.41%, with a market capitalization of 3.831 billion [2] - Yongshun Biological (永顺生物) rose by 3.94%, with a market capitalization of 2.742 billion [2] - Dezhan Health (德展健康) increased by 3.51%, with a market capitalization of 10.5 billion [2] - Junzheng Group (君正集团) rose by 3.37%, with a market capitalization of 46.6 billion [2] - Kanghua Biological (康华生物) increased by 3.19%, with a market capitalization of 10.4 billion [2] Group 2: Market Context - The 2025 version of the Chikungunya virus treatment plan emphasizes preventive measures such as eliminating mosquito breeding grounds and using repellents [1] - There is currently no available vaccine for the Chikungunya virus in China, which may drive demand for vaccine development [1] - Free nucleic acid screening for Chikungunya virus is being conducted in Lecong Town, Shunde District, targeting close contacts of confirmed cases [1]